• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BCOR 基因改变与血液系统疾病。

BCOR gene alterations in hematologic diseases.

机构信息

Institute of Hematology, Center for Hemato-Oncological Research (CREO), University of Perugia, Perugia, Italy.

出版信息

Blood. 2021 Dec 16;138(24):2455-2468. doi: 10.1182/blood.2021010958.

DOI:10.1182/blood.2021010958
PMID:33945606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8887995/
Abstract

The BCL6 corepressor (BCOR) is a transcription factor involved in the control of embryogenesis, mesenchymal stem cells function, hematopoiesis, and lymphoid development. Recurrent somatic clonal mutations of the BCOR gene and its homolog BCORL1 have been detected in several hematologic malignancies and aplastic anemia. They are scattered across the whole gene length and mostly represent frameshifts (deletions, insertions), nonsense, and missence mutations. These disruptive events lead to the loss of full-length BCOR protein and to the lack or low expression of a truncated form of the protein, both consistent with the tumor suppressor role of BCOR.BCOR and BCORL1 mutations are similar to those causing 2 rare X-linked diseases: oculofaciocardiodental (OFCD) and Shukla-Vernon syndromes, respectively. Here, we focus on the structure and function of normal BCOR and BCORL1 in normal hematopoietic and lymphoid tissues and review the frequency and clinical significance of the mutations of these genes in malignant and nonmalignant hematologic diseases. Moreover, we discuss the importance of mouse models to better understand the role of Bcor loss, alone and combined with alterations of other genes (eg, Dnmt3a and Tet2), in promoting hematologic malignancies and in providing a useful platform for the development of new targeted therapies.

摘要

BCL6 核心抑制因子(BCOR)是一种参与胚胎发生、间充质干细胞功能、造血和淋巴发育控制的转录因子。在几种血液恶性肿瘤和再生障碍性贫血中检测到 BCOR 基因及其同源物 BCORL1 的反复体细胞克隆突变。它们遍布整个基因长度,主要代表移码(缺失、插入)、无义和错义突变。这些破坏性事件导致全长 BCOR 蛋白的丢失和截短形式的蛋白缺乏或低表达,这两者都与 BCOR 的肿瘤抑制作用一致。BCOR 和 BCORL1 突变与分别导致 2 种罕见的 X 连锁疾病:眼面心齿骨(OFCD)和 Shukla-Vernon 综合征的突变相似。在这里,我们专注于正常 BCOR 和 BCORL1 在正常造血和淋巴组织中的结构和功能,并回顾这些基因在恶性和非恶性血液病中的突变的频率和临床意义。此外,我们讨论了小鼠模型的重要性,以更好地了解 Bcor 缺失单独和与其他基因(例如,Dnmt3a 和 Tet2)改变相结合在促进血液恶性肿瘤中的作用,并为开发新的靶向治疗提供有用的平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cfb/8887995/27f379e74fdf/bloodBLD2021010958absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cfb/8887995/27f379e74fdf/bloodBLD2021010958absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cfb/8887995/27f379e74fdf/bloodBLD2021010958absf1.jpg

相似文献

1
BCOR gene alterations in hematologic diseases.BCOR 基因改变与血液系统疾病。
Blood. 2021 Dec 16;138(24):2455-2468. doi: 10.1182/blood.2021010958.
2
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.全外显子组测序鉴定出正常核型急性髓细胞白血病中的 BCOR 体细胞突变。
Blood. 2011 Dec 1;118(23):6153-63. doi: 10.1182/blood-2011-07-365320. Epub 2011 Oct 19.
3
Clarifying the impact of polycomb complex component disruption in human cancers.阐明多梳蛋白复合体成分破坏在人类癌症中的影响。
Mol Cancer Res. 2014 Apr;12(4):479-84. doi: 10.1158/1541-7786.MCR-13-0596. Epub 2014 Feb 10.
4
Age-Related Co-Expression of BCOR and BCORL1 mRNA in Acute Myeloid Leukemia.急性髓系白血病中BCOR和BCORL1 mRNA的年龄相关共表达
Clin Lab. 2020 Aug 1;66(8). doi: 10.7754/Clin.Lab.2020.191119.
5
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.BCOR 和 BCORL1 突变在骨髓增生异常综合征及相关疾病中的作用。
Blood. 2013 Oct 31;122(18):3169-77. doi: 10.1182/blood-2012-11-469619. Epub 2013 Sep 18.
6
Nuclear import of transcriptional corepressor BCOR occurs through interaction with karyopherin α expressed in human periodontal ligament.核输入转录核心抑制因子 BCOR 通过与在人牙周韧带中表达的核转运蛋白 α 的相互作用发生。
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):67-73. doi: 10.1016/j.bbrc.2018.10.158. Epub 2018 Nov 2.
7
BCOR analysis in patients with OFCD and Lenz microphthalmia syndromes, mental retardation with ocular anomalies, and cardiac laterality defects.对患有眼脑面骨发育不全和伦茨小眼综合征、伴有眼部异常的智力障碍以及心脏左右不对称缺陷患者的BCOR分析。
Eur J Hum Genet. 2009 Oct;17(10):1325-35. doi: 10.1038/ejhg.2009.52. Epub 2009 Apr 15.
8
Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.表观遗传调控因子基因 BCOR 突变的动力学及其对骨髓增生异常综合征患者低甲基化药物反应的预测价值。
Clin Epigenetics. 2021 Aug 30;13(1):169. doi: 10.1186/s13148-021-01157-8.
9
Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR.眼面心牙综合征和伦茨小眼综合征是由BCOR中不同类型的突变引起的。
Nat Genet. 2004 Apr;36(4):411-6. doi: 10.1038/ng1321. Epub 2004 Mar 7.
10
Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.其他表观遗传调节剂的并发突变预示着 BCOR 突变性骨髓增生异常综合征有更好的预后。
J Clin Pathol. 2020 Apr;73(4):209-212. doi: 10.1136/jclinpath-2019-206132. Epub 2019 Nov 26.

引用本文的文献

1
, , and Mutations in Pediatric Leukemias.小儿白血病中的 、 和 突变
Cancers (Basel). 2025 Jul 23;17(15):2443. doi: 10.3390/cancers17152443.
2
Hyperandrogenism-induced Athletic Excellence in a Young Patient with Adrenocortical Carcinoma: 10 Years of Remission.肾上腺皮质癌年轻患者中高雄激素血症诱导的卓越运动能力:10年缓解期
JCEM Case Rep. 2025 Jul 31;3(9):luaf170. doi: 10.1210/jcemcr/luaf170. eCollection 2025 Sep.
3
Progress in the Genetics of Myelodysplastic Syndromes with a Latin American Perspective.从拉丁美洲视角看骨髓增生异常综合征的遗传学进展

本文引用的文献

1
Modeling and targeting of erythroleukemia by hematopoietic genome editing.通过造血基因组编辑对红白血病进行建模和靶向治疗。
Blood. 2021 Mar 25;137(12):1628-1640. doi: 10.1182/blood.2020009103.
2
The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma.BCOR 突变在成熟 T 细胞淋巴瘤中高度频发且致癌。
BMC Cancer. 2021 Jan 19;21(1):82. doi: 10.1186/s12885-021-07806-8.
3
Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.异常调控的 Polycomb 抑制复合物功能在血液系统恶性肿瘤中的致病影响。
Genes (Basel). 2025 Jun 2;16(6):687. doi: 10.3390/genes16060687.
4
Impact of BCOR/BCORL1 mutation on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients.BCOR/BCORL1突变对急性髓系白血病患者异基因造血干细胞移植结局的影响
Ann Hematol. 2025 Apr 9. doi: 10.1007/s00277-025-06346-6.
5
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice.Bcor缺失促进小鼠慢性淋巴细胞白血病向Richter转化,且与Notch1激活有关。
Leukemia. 2025 May;39(5):1157-1168. doi: 10.1038/s41375-025-02557-y. Epub 2025 Mar 20.
6
Hematopoietic stem cell transplantation and immunosuppressive therapy: implications of clonal haematopoiesis.造血干细胞移植与免疫抑制治疗:克隆性造血的影响
Ann Hematol. 2025 Mar;104(3):1877-1886. doi: 10.1007/s00277-024-06152-6. Epub 2025 Jan 28.
7
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients.非KMT2A重排的B-ALL患者在CD19 CAR-T治疗下谱系转换的动态演变
Leukemia. 2025 Jan;39(1):238-242. doi: 10.1038/s41375-024-02449-7. Epub 2024 Oct 31.
8
The immunobiology of myelodysplastic neoplasms: a mini-review.骨髓增生异常肿瘤的免疫生物学:一篇小型综述。
Front Immunol. 2024 Sep 16;15:1419807. doi: 10.3389/fimmu.2024.1419807. eCollection 2024.
9
Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies.纳米技术在淋巴恶性肿瘤的检测和治疗中的进展。
Int J Mol Sci. 2024 Aug 26;25(17):9253. doi: 10.3390/ijms25179253.
10
Unlocking reproducible transcriptomic signatures for acute myeloid leukaemia: Integration, classification and drug repurposing.解锁急性髓系白血病可重现的转录组学特征:整合、分类和药物再利用。
J Cell Mol Med. 2024 Sep;28(17):e70085. doi: 10.1111/jcmm.70085.
Int J Mol Sci. 2020 Dec 23;22(1):74. doi: 10.3390/ijms22010074.
4
Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis.一般人群中的红细胞增多症:临床特征及与克隆性造血的关系。
Blood Adv. 2020 Dec 22;4(24):6353-6363. doi: 10.1182/bloodadvances.2020003323.
5
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice.Bcor 缺乏扰乱红系巨核细胞生成,并与 Dnmt3a 缺失协同作用导致小鼠急性红细胞白血病的发生。
Leukemia. 2021 Jul;35(7):1949-1963. doi: 10.1038/s41375-020-01075-3. Epub 2020 Nov 6.
6
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.骨髓纤维化和原发性血小板增多症向白血病的演变:基因组特征可预测转化时间。
Blood Adv. 2020 Oct 13;4(19):4887-4897. doi: 10.1182/bloodadvances.2020002271.
7
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.JAK2S523L,一种在JAK2V617F-骨髓增殖性肿瘤关键自调控残基上的新型功能获得性突变。
Blood Adv. 2020 Sep 22;4(18):4554-4559. doi: 10.1182/bloodadvances.2019001283.
8
BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC Activity.BCOR 与 MLL-AF9 的结合对于白血病的发生是必需的,通过改变 EYA1、SIX 和 MYC 的活性。
Blood Cancer Discov. 2020 Sep;1(2):162-177. doi: 10.1158/2643-3230.BCD-20-0036.
9
Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.维奈托克联合低甲基化药物治疗急变期骨髓增殖性肿瘤:12例患者的初步经验
Br J Haematol. 2020 Dec;191(5):e120-e124. doi: 10.1111/bjh.17084. Epub 2020 Sep 18.
10
Small Round Blue Cell Sarcoma Other Than Ewing Sarcoma: What Should an Oncologist Know?小圆细胞蓝色瘤肉瘤,非尤文氏肉瘤:肿瘤学家应了解哪些内容?
Curr Treat Options Oncol. 2020 Sep 1;21(11):90. doi: 10.1007/s11864-020-00785-1.